Navigation Links
New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
Date:10/25/2008

nzymes (ALT and AST) were seen in patients; these increases were generally mild and reversible, with no evidence of hepatic injuries. Laboratory changes, including increases in lipids (total cholesterol, LDL, HDL, triglycerides) and decreases in neutrophils and platelets, were seen in patients without association with clinical outcomes. Treatments that suppress the immune system, such as ACTEMRA, may cause an increase in the risk of malignancies.

About IL-6

IL-6 is a common protein found in all joints in the body and is a natural substance that can raise inflammation. Everyone has IL-6 in their body, but people with RA may have too much.

When approved, ACTEMRA will be the first and only medication to specifically target IL-6 in patients with RA.

About Rheumatoid Arthritis

Rheumatoid arthritis is a progressive, systemic autoimmune disease characterized by inflammation of the membrane lining in the joints. This inflammation causes a loss of joint shape and function, resulting in pain, stiffness and swelling, ultimately leading to irreversible joint destruction and disability. Characteristics of RA include redness, swelling, pain and movement limitation around joints of the hands, feet, elbows, knees and neck that leads to loss of function. In addition, the systemic symptoms of RA include fatigue, decreased hemoglobin, osteoporosis and may contribute to shortening life expectancy by affecting major organ systems. After 10 years, less than 50 percent of patients can continue to work or function normally on a daily basis. RA affects more than 21 million people worldwide with approximately 1.3 million adults affected in the United States.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche
'/>"/>

SOURCE Hoffmann-La Roche Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
3. Life Recovery Systems Receives NIH Grant to Study Expanded Use of Its ThermoSuit System
4. Mindset Media Study Reveals Which Independent Voters Favor Obama Vs. McCain
5. Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkins Lymphoma
6. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
7. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
8. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
9. Whatcom County, Washington Participating in NIH Study of Cardiac Arrest Resuscitation Techniques
10. Facet Solutions Announces Completion of 6 Month Follow-Up in US Pilot Study
11. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 The spinal column is one of the ... carried to and from the brain through the column control ... Injury or ailment here can be life altering, and leave ... control over their body. Though back injury and disease can ... are more options available to make things better than ever ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - The Canadian Epilepsy Alliance ... comic series designed to educate children about the most common ... Medikidz Explain Epilepsy comic series tells a fictional ... navigating middle school while living with epilepsy. ... there is still so much misinformation and lack of awareness ...
(Date:8/21/2014)... , N.Y. and HAMBURG, Germany , ... announced it is collaborating with Deutsches Elektronen-Synchrotron ( DESY ... Germany , to speed up management and storage ... Big Data and Analytics architecture based on IBM ... per second of data at peak performance and help ...
Breaking Medicine Technology:Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3
... ROCKVILLE, Md., Dec. 16, 2010 Novavax, Inc. (Nasdaq: ... clinical trial to evaluate a new vaccine candidate to prevent ... U.S. Food and Drug Administration (FDA) and is no longer ... had received a question from the FDA regarding chemistry, manufacturing ...
... Resources, one of the world,s leading research and ... that, owing to its superb efficacy, acceptable safety ... Ironwood/Forest/Almirall/Astellas,s linaclotide will emerge as the market leader ... In 2019, linaclotide will garner blockbuster sales of ...
Cached Medicine Technology:NOVAVAX Receives FDA Clearance to Launch Phase I RSV Vaccine Clinical Trial 2NOVAVAX Receives FDA Clearance to Launch Phase I RSV Vaccine Clinical Trial 3NOVAVAX Receives FDA Clearance to Launch Phase I RSV Vaccine Clinical Trial 4For Treatment of Irritable Bowel Syndrome, Linaclotide Will Emerge as the Market Leader and Will Achieve Blockbuster Status in 2019 2
(Date:8/22/2014)... (PRWEB) August 23, 2014 This ... (Instruments (Workstations, Liquid Handling Systems), Consumables (Tubes), Kits ... Users (Molecular Diagnostics) - Global Forecast to 2018" ... 2013 and is poised to grow at a ... reach $5,672.0 million by 2018. , Browse 98 ...
(Date:8/22/2014)... 2014 With the stage set for ... Store Expo - which will be held in Boston ... op-ed in its online opinion section, Podium. The ... is co-authored by Steven C. Anderson, IOM, CAE, president ... of the MCPHS University School of Pharmacy – Worcester/Manchester. ...
(Date:8/22/2014)... 2014 Millennium Treatment Group has recently noticed ... high level of drug use among teenagers. The treatment facility ... addiction and work to minimize drug abuse. , America is ... drug addiction in history. According to the National Institute ... Americans aged 12 or older—or 9.2 percent of the population—had ...
(Date:8/22/2014)... The regional economy is about to ... on the grow again. The plant will invest ... to boost production of the popular Highlander midsize sport ... investment to $4 billion. This step allows Toyota to ... flexibility to adjust its product mix to meet changing ...
(Date:8/22/2014)... A Penn Medicine team has found that targeted ... urinary tract infections in hospital patients with urinary ... alert was simplified, the rate of improvement dramatically ... their patients need urinary catheters in the first ... need for catheters that have not been removed ...
Breaking Medicine News(10 mins):Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 2Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 3Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 2Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 3
... dubious DEA raids on,legal medical marijuana dispensaries, LOS ANGELES, ... federal government needs to reclassify marijuana. People who,need it should ... The Price Is,Right and Power of 10 host Drew Carey ... on drugs., Voters in 12 states have legalized medical ...
... Minn. -- A Mayo Clinic study of a drug that ... demonstrates that the drug may also be effective in treating ... The study, which was done in mouse models, is featured ... , The National Cancer Institute reports that of 240,510 ...
... pregnant, the probability is much greater that her child ... according to a new Nordic study. The investigation ... in collaboration with international colleagues, and is available online ... comprising more than 12,500 children in Sweden, Finland, and ...
... 1 Dynavax Technologies,Corporation (Nasdaq: DVAX ) announced ... will present an overview of the,company at two investor ... Ostrach will present at the CIBC World Markets 18th ... a.m. ET (5:35,a.m. PT). In addition, Ostrach will present ...
... 1 Amira Pharmaceuticals, Inc. announced,completion of the ... discovered oral drug candidate for the treatment of ... announced the start,of a Phase 1 trial for ... the,same inflammatory response. AM103 and AM803 are ...
... plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) the,global specialty biopharmaceutical ... Financial Highlights - Product sales up 41% to $543.1 ... - Net cash provided by operating activities up 51% ... expected to be at least 30% (Q2 guidance: at,least 25%). ...
Cached Medicine News:Health News:Drew Carey Defends Medical Marijuana 2Health News:Mayo Clinic study shows drug could effectively treat, prevent the spread of breast cancer 2Health News:Mayo Clinic study shows drug could effectively treat, prevent the spread of breast cancer 3Health News:Overweight mothers run greater risk of having hyperactive children 2Health News:Dynavax to Present at CIBC World Markets and Acumen BioFin Rodman and Renshaw Healthcare Conferences 2Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 2Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 3Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 3Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 4Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 5Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 6Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 7Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 8Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 9Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 10Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 11Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 12Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 13Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 14Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 15Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 16Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 17Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 18Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 19Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 20Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 21Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 22Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 23Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 24Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 25Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 26Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 27Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 28Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 29
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: